WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 15, 2012--
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, announced today that it has priced its previously announced
offering of senior notes:
-
$500 million aggregate principal amount of 1.850% senior notes due
2018 at an issue price of 99.985% of the principal amount, and
-
$800 million aggregate principal amount of 3.150% senior notes due
2023 at an issue price of 99.475% of the principal amount.
The issuance of the notes is expected to close on August 22, 2012. The
notes will pay interest on a semi-annual basis.
The company plans to use the proceeds of the offering to fund its
acquisition of One Lambda and for other general corporate purposes. The
One Lambda acquisition was announced by the company on July 16, 2012,
for an aggregate purchase price of approximately $925 million.
The joint book-running managers for the offering are Goldman, Sachs &
Co., J.P. Morgan Securities LLC, RBS Securities Inc., Barclays Inc.,
Deutsche Bank Securities Inc., Merrill Lynch, Pierce, Fenner & Smith
Incorporated, and Morgan Stanley & Co. LLC.
Thermo Fisher has filed a registration statement on Form S-3 (including
a prospectus) with the Securities and Exchange Commission (the “SEC”)
for this offering. Prospective investors should read the prospectus
forming a part of that registration statement and the prospectus
supplement related to the offering and the other documents that the
company has filed with the SEC for more complete information about the
company and this offering. These documents are available at no charge by
visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, these documents will be made available upon request by
the company or by any active joint book-running manager for the
offering. Interested parties may obtain a prospectus or the related
preliminary prospectus supplement from Goldman, Sachs & Co. by directing
a request to 200 West Street, New York, NY 10282, Attn: Prospectus
Department, or by calling 866-471-2526; from J.P. Morgan Securities LLC
by directing a request to 383 Madison Avenue, New York, NY 10179, Attn:
High Grade Syndicate Desk – 3rd Floor, or by calling 212-834-4533; or
from RBS Securities Inc. by directing a request to 600 Washington
Boulevard, Stamford, CT 06901, Attn: Debt Capital Markets Syndicate, or
by calling 866-884-2071.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any offer,
solicitation or sale of the notes in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such jurisdiction.
Source: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron
O’Brien, 781-622-1242
ron.obrien@thermofisher.com
or
Investor
Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
